Global Cannabinoid Solutions (GCS) and The American Journal of Endocannabinoid Medicine (AJEM) today announced its strategic alliance, to deliver immediate and efficient access to the latest scientific knowledge, education and peer-reviewed cannabis research.
GCS’ Managing Director Chris Tasker, who holds a Masters (MSc) in cannabis medical research said
“This partnership brings world-leading cannabis science to support the UK in overcoming the key issues impacting cannabis patients and citizens on the frontline. To open this dialogue we are launching with a series of online and publicly roundtable events, drawing attention to urgent patient needs. We look forward to working with UK officials and industry leaders over the coming months.”
The partnership will bring together world leading endocannabinoid scientists and academics, to inform policy makers and evolve the cannabis debate. The main focus of this alliance will be to highlight the societal implications that current UK legislation brings, raise awareness of the science behind the plant, its unique relationship with humanity, and promote the benefits of scientifically grounded debate in evolving cannabis research in the UK.
AJEM educational materials will be at the core of this scientific initiative by:
Connecting and applying the latest cannabis science & research with the UK
Establishing UK endocannabinoid system (ECS) research infrastructure to support cannabis-based medicinal products for use in humans (CBMP)
Support evidence-based policy and inform legislation and regulation with forefront endocannabinoid science
Engaging with UK institutions to understand their needs and create tailored educational programs to facilitate the next generation of research excellence
AJEM Editor and Chief, Jahan Marcu PhD comments
“The backbone of The American Journal of Endocannabinoid Medicine is the scientific acumen of its Editorial Board. The AJEM faculty, armed with the science behind the endocannabinoid system, is excited about the opportunity to partner and work with the medical community and government officials in the UK regarding the science behind the ECS and the cannabinoids that engage with it.”
We welcome all conversations and look forward to building an informed and multidisciplinary debate. Speak to us today and help us connect this knowledge with those in need so that together, we can lay the foundations for the future of cannabinoid medicine.
Global Cannabinoid Solutions
CEO Chris Tasker: Chris@globalcannabinoidsolutions.com
American Journal of Endocannabinoid Medicine